Kornimate/medical-research-clean huggingface dataset:
docetaxel + prednisone with or without radiation for castrate resistant prostate cancer

Conditions: PROSTATE CANCER

Summary: the main purpose of this study is to find out whether adding radiation therapy to the standard treatment of chemotherapy for prostate cancer is tolerated well and is more effective than the standard treatment of chemotherapy alone

most physicians would consider chemotherapy to be the standard for prostate cancer. in this study all participants will receive the standard chemotherapy. in addition, half the participants will also receive radiation therapy. it is hoped that the radiation therapy will provide additional benefit. the use of radiation therapy and chemotherapy for patients with this kind of cancer is not considered standard treatment at the present time. participants will be randomized into groups (or arms) by a computer program. participants randomized to arm 1 will receive chemotherapy alone. participants in arm 2 will receive chemotherapy and radiation therapy. participants in both groups (arm 1 and arm 2) will receive standard chemotherapy with docetaxel and prednisone. docetaxel is given through a needle in a vein in the arm every 3 weeks or 21 days. participants will take a prednisone tablet once per day until 21 days after the last dose of docetaxel. in addition, all participants will be given a drug called dexamethasone twice daily for 6 doses to help with the side effects of docetaxel. participants in arm 2 will first receive radiation therapy to the pelvis and prostate gland. radiation therapy will be delivered once a day, five days a week for a total of 8-9 weeks. then beginning 4-6 weeks after the end of radiation therapy, chemotherapy will be given, as described above. in both arms, the total number of cycles of docetaxel and prednisone will depend upon how the tumor responds to these drugs. all patients should receive a minimum of three cycles of chemotherapy.

Eligibility criteria:
inclusion criteria: * participants must have a diagnosis of castrate resistant prostate cancer. * participants must be 18 years old or older. * biopsy of tissue from the prostate or enlarged lymph nodes may be required. * patients must sign study specific informed consent prior to study entry. * men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards. exclusion criteria: * participants cannot have prior chemotherapy for prostate cancer. * participants cannot have prior radiation therapy to the pelvis.

Keywords: prostate cancer non metastatic prostate cancer oligometastatic prostate cancer
study of the relationship between clinical, imaging and biological data in patients with squamous cell carcinoma of the tongue

Conditions: Soft Tissue Tumors of the Tongue; Squamous Cell Carcinoma; Proton Magnetic Resonance Spectroscopy; Transcriptomics

Summary: squamous cell carcinoma (scc) could be a very aggressive cancer and has a bad prognosis if not detected early and thus is associated with high mortality. the development of simple and reliable biomarkers for the early detection of scc is one of the solutions to better diagnose, treat these tumors, evaluate and monitor treatments, and hence reduce mortality. in a previous work, the investigators demonstrated the ability of proton magnetic resonance spectroscopy (1h-mrs) to non-invasively assess spectroscopic and metabolic profiles of tongue tissue in healthy subjects. in the present work, the investigators challenge the use of in-vivo 1h-mrs as a potential method for non-invasive metabolic monitoring of patients with squamous cell carcinoma of the tongue undergoing therapy. thus the main objective is to study the spectroscopic and metabolic differences, e.g. including variation in the metabolite tma-cho (trimethylamine-choline), of tongue tissue between healthy subjects and in patients with squamous cell carcinoma of the tongue, before and after surgery.


Eligibility criteria:
inclusion criteria: patients: * patients from the maxillofacial surgery department of the amiens-picardie university hospital treated for histologically confirmed squamous cell carcinoma of the tongue * patients who have not yet been treated, either surgically or by neoadjuvant treatment * patients with a tumor of minimum dimensions of 15 mm in long axis * patients without contraindication to mri * patients over 18 years old * patients who have provided free and informed written consent * patients benefiting from a social security system healthy volunteers: * subjects without a history of cancer of the upper aerodigestive tract * subjects without contraindication to mri * subjects over 18 years old * subjects who have provided free and informed written consent * subjects benefiting from a social security system exclusion criteria: * patients: * patients with a lingual tumor measuring less than 15 mm in long axis patients and healthy volunteers: * patients with other histological types of cancer, or other locations * subjects with a contraindication to mri * subjects under 18 years old * pregnant or breastfeeding women * persons under guardianship, curators, protection of justice or deprived of liberty

Keywords: tongue tissue squamous cell carcinoma proton magnetic resonance spectroscopy 1h-mrs spectroscopic and metabolic profile noninvasive biomarkers transcriptomics
effect of avastin in juxtafoveal telangiectasias

Conditions: Telangiectasis

Summary: evaluation of efficacy of intravitreal injection of bevacizumab in patients with yuxtafoveal telangiectasias

after diagnose yuxtafoveal telangiectasias secondary to branch retinal vein occlusion and with idiopathic ethiology by clinical signs and fluorescein angiogram (fa)findings we treated patients with intravitreal injection of bevacizumab (2.5mg/0.1ml). we performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate etdrs best corrected visual acuity (bcva), fluorescein angiogram (fa) and optical coherence tomography (oct)findings. we found an improvement in visual acuity and reduction of fa leakage and decrease retinal thickness in oct.

Eligibility criteria:
inclusion criteria: * patients with telangiectasias secondary to branch retinal vein occlusion * patients with idiopathic juxtafoveal retinal telangiectasias exclusion criteria: * diabetic retinopathy and diabetic macular edema * hypertensive retinopathy * choroidal neovascularization

Keywords: telangiectasias leakage bevacizumab telangiectasias secondary to branch retinal vein occlusion (brvo) idiopathic juxtafoveal retinal telangiectasias
convalescent plasma for patients with covid-19: a pilot study

Conditions: Coronavirus; Coronavirus Infection

Summary: convalescent plasma (cp) has been used in recent years as an empirical treatment strategy when there is no vaccine or treatment available for infectious diseases. in the latest viral epidemics, such as the ebola outbreak in west africa in 2014, the world health organization issued a document outlining a protocol for the use of whole blood or plasma collected from patients who have recovered from the ebola virus disease by transfusion to empirically treat local infectious outbreaks.

the process is based on obtaining plasma from patients recovered from covid-19 in colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (covid-19). our group has reviewed the scientific evidence regarding the application of convalescent plasma for emergency viral outbreaks and has recommended the following protocol

Eligibility criteria:
inclusion criteria:fulfilling all the following criteria 1. aged between 18 and 60 years, male or female. 2. hospitalized participants with diagnosis for covid 19 by real time - polymerase chain reaction. 3. without treatment. 4. moderate cases according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 6)". 5. confusion, urea, respiratory rate, blood pressure-65 (curb-65) \>= 2. 6. sequential organ failure assessment score (sofa) \< 6. 7. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. female subjects who are pregnant or breastfeeding. 2. patients with prior allergic reactions to transfusions. 3. critical ill patients in intensive care units. 4. patients with surgical procedures in the last 30 days. 5. patients with active treatment for cancer (radiotherapy or chemotherapy). 6. hiv diagnosed patients with viral failure (detectable viral load\> 1000 copies / ml persistent, two consecutive viral load measurements within a 3 month interval, with medication adherence between measurements after at least 6 months of starting a new regimen antiretrovirals). 7. patients who have suspicion or evidence of coinfections. 8. end-stage chronic kidney disease (glomerular filtration rate \<15 ml / min / 1.73 m2). 9. child pugh c stage liver cirrhosis. 10. high cardiac output diseases. 11. autoimmune diseases or immunoglobulin a nephropathy. 12. patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study.

Keywords: covid-19 coronavirus disease 2019
study of high-dose melphalan and autologous stem cell transplantation in patients with primary light chain amyloidosis

Conditions: Amyloidosis

Summary: objectives: i. determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. ii. determine the toxicity of this regimen in these patients.

protocol outline: patients may receive induction chemotherapy before study entry. patients then receive filgrastim (g-csf) or another growth factor for 4-6 days as peripheral blood stem cell (pbsc) mobilization. pbsc (or bone marrow) is harvested over 2-3 days. patients receive high-dose melphalan iv over 30 minutes twice daily on days -2 and -1. pbsc and/or bone marrow is reinfused on day 0. patients receive g-csf beginning on day 0 and continuing until blood counts recover. this course may be repeated 4-12 weeks later. patients are followed every 3 months for 1 year and then annually for 5 years.

Eligibility criteria:
protocol entry criteria: disease characteristics * histologically confirmed primary amyloidosis * ineligible for other high priority national or international study prior/concurrent therapy * biologic therapy: concurrent participation in gene therapy trials allowed * chemotherapy: prior chemotherapy allowed no other concurrent chemotherapy * endocrine therapy: no concurrent steroids unless given with amphotericin b, for adrenal failure, or for septic shock no concurrent hormones except for non-disease-related conditions (e.g., insulin for diabetes) * other: no concurrent barbiturates or acetaminophen concurrent participation in supportive care trials allowed patient characteristics * performance status: ecog 0-3 * hepatic: bilirubin less than 2 times normal * renal: creatinine less than 2.5 mg/dl or on stable hemodialysis * pulmonary: dlco at least 60% predicted or clearance by pulmonologist * other: hiv negative

Keywords: amyloidosis arthritis & connective tissue diseases genetic diseases and dysmorphic syndromes hematopoietic/lymphoid cancer oncologic disorders plasma cell neoplasm primary systemic amyloidosis rare disease
a pilot study to evaluate the rox anastomotic coupler system in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate the safety and preliminary performance of the rox anastomotic coupler system (acs), with standard of care (as defined per gold) in patients with chronic obstructive pulmonary disease (copd) as compared to standard of care alone.

chronic obstructive pulmonary disease (copd) is a chronic disease that leads to irreversible changes in the lung structure, but also to systemic changes in the body that can influence the severity of the disease. the irreversible changes to the lungs can be seen in limitations to the pulmonary function. the purpose of this clinical investigation is to evaluate the performance and efficacy of the rox percutaneous anastomotic coupler system.

Eligibility criteria:
inclusion criteria: * diagnosis of advanced chronic obstructive pulmonary disease (copd) must be made on the basis of current findings, medical history and physical examination. exclusion criteria: * subjects not meeting stage iii or iv chronic obstructive pulmonary disease (copd) * subjects with significant comorbidities * subjects not qualifying because of physical or psychological condition that may put them at risk of participating

Keywords: lung disease chronic airflow obstruction chronic bronchitis pulmonary emphysema walk
cancer: rapid diagnostics and immune assessment for sars-cov-2 (covid-19)

Conditions: Infectious Disease; Cancer; Coronavirus Infection

Summary: people with cancer may be at higher risk of poor outcomes with covid-19 infection. this observational study aims to describe the clinical course of covid-19 infection in people with cancer and evaluate the utility of antibody and antigen tests for covid-19. the results of this study will inform clinical practice in the management of cancer patients with covid-19.

patients with cancer are thought to have a weakened immune system and small observational case series have suggested patients with cancer are at a higher risk of poor outcome from covid-19. however, the clinical course of covid-19 infection amongst cancer patients is not known. in addition, it is unclear when it is appropriate for cancer patients who have recovered from covid-19 infection to resume anti-cancer therapy. there is unmet need for diagnostic assays for covid-19 including tests which can rapidly determine whether the virus has been cleared of the covid-19. lateral flow assays investigated in this study are rapid and simple diagnostic tools which can assist in timely diagnostics to inform clinical decision making. this observational study aims to describe the immunological dynamics and clinical course of covid-19 in cancer patients and evaluate covid-19 antibody and antigen lateral flow assays. the information from our study will add significantly to the understanding of covid-19 diagnostics and will improve the evidence-base for the management of cancer patients. furthermore, data from this study could inform the timing and treatment for cancer patients who have recovered from covid-19 infection.

Eligibility criteria:
inclusion criteria: * suspected covid-19 infection undergoing diagnostic testing by sars-cov-2 rt-pcr * metastatic or advanced solid organ malignancy, including lymphoma or early stage solid organ malignancy having received therapy (radiotherapy, chemotherapy or targeted agents) * patient is ≥ 18 years of age. * patient can understand the patient information sheet and is able to provide written informed consent. exclusion criteria: * there are no exclusion criteria for this study.

Keywords: covid-19 sars-cov-2 cancer coronavirus infection
proof of concept (design validation) in patient with hard to heal wounds such as pressure ulcer, diabetic foot ulcer and leg ulcer, leia

Conditions: Leg Ulcer; Diabetic Foot Ulcer; Pressure Ulcer

Summary: the purpose of this reseach study is to determine mölnlycke health care´s leia dressing performance properties is fulfilled and that the dressing is safe when used on wound types such as pressure ulcer, leg ulcer, and diabetic foot ulcer.


Eligibility criteria:
inclusion criteria: * low to highly exuding chronic wound(wound history \> 2 months) such as leg ulcer, pressure ulcer category iii to iv or diabetic foot ulcer * male of female, 18 years and above * signed informed consent form exclusion criteria: * pregnancy or lactation * wound size not suitable for the wound dressing size * known allergy/hypersensitivity to any of the components in the dressing
manual therapy and exercise in patients with cervicogenic headache

Conditions: Cervicogenic Headache

Summary: hypothesis: the group of cervicogenic headache patients receiving upper cervical and upper thoracic thrust manipulation will demonstrate significant and clinically important changes in outcomes when compared to the mobilization and exercise group.

patients with cervicogenic headache will be randomized to receive 6-8 sessions over 2-4 weeks of either: (1) upper cervical and upper thoracic thrust manipulation, or (2) upper cervical and upper thoracic non-thrust mobilization and range of motion, strength and postural exercises.

Eligibility criteria:
inclusion criteria: * diagnosis of cervicogenic headache as defined by cervicogenic headache international study group criteria * headache frequency of at least one per week for a minimum of 3 months * minimum pain score (nprs) of 2/10 and minimum disability score (ndi) of 10/50 exclusion criteria: * bilateral headaches * presence of any of the following atherosclerotic risk factors: hypertension, diabetes, heart disease, stroke, transient ischemic attack, peripheral vascular disease, smoking, hypercholesterolemia or hyperlipidemia * red flags noted in the patient's neck medical screening questionnaire (i.e. tumor, fracture, metabolic diseases, ra, osteoporosis, prolonged history of steroid use, etc.) * history of whiplash injury within the last 6 weeks * diagnosis of cervical spinal stenosis * bilateral upper extremity symptoms * evidence of central nervous system involvement, to include hyperreflexia, sensory disturbances in the hand, intrinsic muscle wasting of the hands, unsteadiness during walking, nystagmus, loss of visual acuity, impaired sensation of the face, altered taste, the presence of pathological reflexes (i.e. positive hoffman's and/or babinski reflexes) * two or more positive neurologic signs consistent with nerve root compression, including any two of the following: * muscle weakness involving a major muscle group of the upper extremity. * diminished upper extremity deep tendon reflex of the biceps, brachioradialis, triceps or superficial flexors * diminished or absent sensation to pinprick in any upper extremity dermatome * prior surgery to the neck or thoracic spine. * involvement in litigation or worker's compensation regarding their neck pain and/or headaches. * physical therapy or chiropractic treatment for neck pain or headache in the 3 months before baseline examination. * any condition that might contraindicate spinal manipulative therapy

Keywords: cervicogenic headache neck pain manipulation mobilization exercise
as-oct study of cornea and tear film parameters in juvenile sle patients

Conditions: Juvenile Systemic Lupus Erythematosus

Summary: the aim of thie study to assess tear film parameters such as tear meniscus height (tmh), tear meniscus area (tma), and tear meniscus depth (tmd). in addition, corneal pachymetry and epithelial thickness maps in juvenile sle patients and compared to healthy subjects of similar age and gender.

juvenile systemic lupus erythematous (sle) is a relapsing and remitting autoimmune connective tissue disorder that can affect many organs such as skin, joints, kidneys, eye, and brain (1) . sle has a global prevalence of 0.3 to 23.2 cases per 100,000. women are more likely than men to develop the disease. four out of the following 11 diagnostic criteria are sufficient for the diagnosis of sle, malar rash, discoid rash, oral ulcers, non-erosive arthritis, serositis, photosensitivity, renal disorder, neurological disorder, hematological disorder, immunological disorder, and presence of antinuclear antibodies. (2,3) ocular manifestations occur in about one third of juvenile sle patients with keratoconjunctivitis sicca being the most common manifestation which is characterized by decreased tear film aqueous layer. scleritis, retinal vasculitis (which is often associated with cns lupus), and papillitis are considered as the most serious ocular manifestations. (4) corneal involvement in juvenile sle affects the superficial epithelium, resulting in superficial punctate keratitis, which is believed to be caused by sjögren\&#39;s syndrome (ss). however, some cases of non-infiltrative and infiltrative peripheral ulcerative keratitis have been identified (5) . schirmer\&#39;s test and fluorescein breakup time test (fbut) are two common clinical tests used to analyze tear film. (6,7) using an in vivo, non- contact technique, anterior segment optical coherence tomography (as- oct) is now used to image the tear film, measure the lower tear film height and area, measure corneal thickness (pachymetry), and measure surface epithelial thickness. (8,9)

Eligibility criteria:
inclusion criteria: - age ≤18 years old. patients with juvenile sle diagnosed by a rheumatologist with no ocular involvement upon clinical examination exclusion criteria: * 1- patients with history of intraocular surgery as cataract surgery ,retinal detachment surgery, anti-glucoma surgery. 2. patients with history of any corneal refractive surgery as lasik, prk. 3. patients with significant media opacity as corneal opacity, cataract. 4. patients with ocular diseases as glaucoma, uveitis. 5. patients with any retinal affection as pathological myopia, macular hole, age related macular degeneration and retinal vascular occlusion. 6. patients with systemic diseases as diabetes mellitus, hypertension, abnormal kidney function.

Keywords: anterior segment optical coherence tomography tear film dry eye juvenile systemic lupus erythematous
pro-vision: patient reported outcomes-based monitoring of vegf-inhibitor side effects in oncology

Conditions: Renal Cell Carcinoma

Summary: the purpose of this study is to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies. this study is specifically investigating this approach in patients taking oral vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitors (tkis) for metastatic renal cell carcinoma (mrcc). participants in this study will receive a survey via email or telephone once a week while receiving treatment with a vegfr tki. the survey will ask about symptoms such as nausea or fatigue and overall quality of life. this survey should take no more than 15 minutes to complete. the survey will be sent directly to the oncology care team. participants will receive a follow-up phone call or message from the team when participants have new or worsening symptoms. the participants will continue to receive surveys for as long as they are receiving a vegf tki treatment.


Eligibility criteria:
inclusion criteria: * adult patients aged 18 years or older * histologically confirmed renal cell carcinoma requiring treatment with vegf tki. * patients may be receiving other concurrent cancer-directed therapy such as immune checkpoint inhibitors. * english or spanish speaking * ability to complete pro surveys (i.e. ability to read/write or access to telephone or internet) * willing and able to meet all study requirements exclusion criteria: all subjects meeting any of the exclusion criteria at baseline will be excluded from study participation. • inability for any reason to complete pro surveys

Keywords: patient reported outcomes vascular endothelial growth factor quality of life adverse effects